spacer
home > epc > Autumn 2014
PUBLICATIONS

European Pharmaceutical Contractor

epc
Autumn 2014

   
Text
PDF
bullet
Business and Finance
Clinical Procurement

Under the Hammer


The number of firms engaging in reverse auctions when procuring strategic services is on the rise. This can damage the buyer as well as the supplier, argue Julia Forjanic Klapproth and Douglas Fiebig at Trilogy Writing and Consulting.
 
view
download pdf
bullet
Marketplace & Business
Intellectual Property

Enhancing Assets


Jackie Maguire of Coller IP contends that businesses could be doing more to fully utilise their intellectual property portfolios. To accommodate the pressures of change and get the most out of assets, companies should plan ahead and engage outside help.


 
view
download pdf
bullet
Clinical Trials: Patient Recruitment & Retention
Social Media

Get Connected


The Medical Research Network's Graham Wylie assures us that the major concerns in using social media in clinical trials are all relatively easy to address, as well as discussing the advantages of utilising such tools – many of which are only just being realised by pharma.
 
view
download pdf
bullet
Legal & Regulatory
Proposed EU Data Protection Regulation

Potential Impact


This year, the European Parliament put forward a new regulation on data protection. Samantha Regenthal of Regenthal Legal & Compliance outlines the impact the legislation could have on the industry if implemented.

 
view
download pdf
bullet
Electronic Solutions
Clinical Trial Innovations

Tech Trends


Drug makers are putting increasing pressure on CROs to conduct clinical trials in more innovative ways. David Blackman at PPD advises that new technologies will not only aid partners in providing a higher quality service, but also add value and efficiency to their own business.

 
view
download pdf
bullet
Clinical Research
Patient Safety

Narratives Reporting Events


Patient safety narratives play an important part in any clinical trial, but are often complex, consuming time and money. Despite this – and in order to ensure transparency and consistency – all guidelines and process steps should be adhered to, says Quanticate’s Yvonne Moores.
 
view
download pdf
bullet
Science & Innovation: Cancer Focus
Phase 1 Oncology Trials

Lessons Learned


New challenges are arising with the growing number and size of Phase 1 oncology trials. Sean Hart at Vector Oncology and Rabinder Buttar at ClinTec International share the best ways to optimise study outcomes.
 
view
Lung Cancer Treatment

Nano Debate: Part 1

Shelley Bowers from Asons Solicitors debates the pros and cons of using nanotechnology in the treatment of non-small cell lung cancer. Although the tool holds much hope for the future, it should be approached with caution as it lacks thorough research.
 
view
download pdf
bullet
Therapeutic Innovation
Ageing Populations

Beyond a Single Pill


Capsugel’s Sven Stegemann describes why a ‘one-size-fits-all’ approach to drug design is no longer sufficient in the treatment of diseases of ageing. Various patient-centric products should be explored – and are sometimes essential to adherence in elderly populations.
 
view
download pdf
bullet
Data Management & IT Solutions
Cloud-Based Compliance Software

Secure Environment


Constantly validated, secure data can be achieved through cloud-based compliance systems. However, several myths surround their implementation – James Brown of Zinc Ahead explains why these can be cast aside.
 
view
download pdf
bullet
LABS & Logistics
Laboratory Relocation

The Right Move


Potential research disruption, damage to samples and heavy costs can strike fear into any company considering a laboratory move. John Best at Andrew Porter Ltd tells us how to make a success of any relocation.
 
view
download pdf
bullet
Review
In Conclusion

Breaking News


Graham Hughes
reviews pharma's recent news items, and suggests that the industry is receiving selective press attention.

 
view
download pdf
bullet
Regional Focus
Russia Focus: Risk-Based Monitoring

Instant Results


While there are huge cost savings to be had from implementing risk-based monitoring, the benefits can take years to surface. Synergy Research Group’s Igor Stefanov and John Barker offer Russia as a solution to those looking for quicker rewards.
 
view
download pdf

Research and Development
Diseases of Ageing

Finding the Trigger


Ciriaco Maraschiello at Harlan Contract Research Services believes that, in order to produce more efficacious treatments for age-related conditions, the triggering mechanisms of these diseases need to be fully understood.

 
view
download pdf

Interview
Industry Interview

Gaining Access


Hunter Walker at Atlantic Research Group discusses accessing and utilising sponsors’ biggest asset – and why today’s pharma industry calls for better analytics and data management.
 
view
download pdf
Industry Interview

Maximum Protection


Neil Coulson at Baker Botts discusses the recent difficulties and developments in the intellectual property field, and advises on how pharma can maintain value.

 
view
download pdf
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

Francine Lane Recipient of 2019 DIA Global Inspire Award

JERSEY CITY – March 21, 2019 – Francine Lane, TrialScope Vice President of Global Transparency, has received a 2019 Global Inspire Award from the Drug Information Association (DIA). Lane, chair of the DIA’s Clinical Trial Disclosure Community, and Robert Paarlberg, past chair, are co-recipients of the Community Engagement Award. The award recognizes DIA community chairs for consistently driving engagement while advancing knowledge and thought leadership within their membership communities.
More info >>

White Papers

Conveying Medical Guidance in Clinical Trials – A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement